Aisha Alharbi

439 total citations
25 papers, 275 citations indexed

About

Aisha Alharbi is a scholar working on Infectious Diseases, Neurology and Surgery. According to data from OpenAlex, Aisha Alharbi has authored 25 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 7 papers in Neurology and 5 papers in Surgery. Recurrent topics in Aisha Alharbi's work include COVID-19 Clinical Research Studies (10 papers), Long-Term Effects of COVID-19 (6 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Aisha Alharbi is often cited by papers focused on COVID-19 Clinical Research Studies (10 papers), Long-Term Effects of COVID-19 (6 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Aisha Alharbi collaborates with scholars based in Saudi Arabia, United States and Belgium. Aisha Alharbi's co-authors include Khalid Eljaaly, Samah Alshehri, Jessica K. Ortwine, Jason M. Pogue, Ramesh Vishwakarma, Khalid Al Sulaiman, Ohoud Aljuhani, Shmeylan Al Harbi, Hisham A. Badreldin and Abdullah Alhammad and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Drugs.

In The Last Decade

Aisha Alharbi

21 papers receiving 269 citations

Peers

Countries citing papers authored by Aisha Alharbi

Since Specialization

Citations

This map shows the geographic impact of Aisha Alharbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aisha Alharbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aisha Alharbi more than expected).

Fields of papers citing papers by Aisha Alharbi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aisha Alharbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aisha Alharbi. The network helps show where Aisha Alharbi may publish in the future.

Co-authorship network of co-authors of Aisha Alharbi

This figure shows the co-authorship network connecting the top 25 collaborators of Aisha Alharbi. A scholar is included among the top collaborators of Aisha Alharbi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aisha Alharbi. Aisha Alharbi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multifocal osteolytic lesions as an initial presentation of mycobacterium riyadhense: Case report and literature review 2025 ·Journal of Infection and Public Health ·(unknown), (unknown), Aisha Alharbi, (unknown), (unknown), Sharif Hala	1
2	Managing Infections in Burn Patients: Strategies and Considerations for Antimicrobial Dosing 2025 ·PubMed ·Abdullah F. Alharthi, Khalid Al Sulaiman, (unknown), (unknown), (unknown), Aisha Alharbi, (unknown), (unknown), Ohoud Aljuhani	0
3	The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study 2024 ·Scientific Reports ·Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B. Korayem, Ali F. Altebainawi, (unknown), (unknown), (unknown), Aisha Alharbi, (unknown), (unknown), (unknown), Omar A. Almohammed, (unknown), (unknown), (unknown), (unknown), (unknown), Ramesh Vishwakarma	4
4	Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report 2024 ·Journal of Infection and Public Health ·(unknown), Aisha Alharbi, (unknown), (unknown), Ihab El‐Hemaidi, (unknown)	0
5	Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia 2024 ·Saudi Pharmaceutical Journal ·Abdulaali R. Almutairi, (unknown), (unknown), (unknown), (unknown), Majed S. Al Yami, (unknown), Omar A. Almohammed, (unknown), (unknown), (unknown), Alaa Bagalagel, Aisha Alharbi, (unknown), (unknown), (unknown)	0
6	Left hand abscess as a paradoxical reaction during treatment of disseminated tuberculosis in immunocompetent patient: case report and review of literature 2024 ·BMC Infectious Diseases ·Aisha Alharbi, (unknown), (unknown), (unknown)	0
7	When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study 2023 ·Journal of Infection and Public Health ·Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, (unknown), (unknown), (unknown), Abrar K. Thabit, (unknown), (unknown), (unknown), (unknown), Aisha Alharbi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ramesh Vishwakarma	1
8	Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study 2022 ·Saudi Pharmaceutical Journal ·Ohoud Aljuhani, Khalid Al Sulaiman, (unknown), Khalid Eljaaly, Aisha Alharbi, (unknown), (unknown), (unknown), (unknown), Ramesh Vishwakarma, Ghassan Al Ghamdi, (unknown), Ghazwa B. Korayem	6
9	The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study 2022 ·International Journal of Infectious Diseases ·Ghazwa B. Korayem, Ohoud Aljuhani, Ali F. Altebainawi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ramesh Vishwakarma, (unknown), Khalid Eljaaly, Aisha Alharbi, (unknown), (unknown), (unknown), Ahmed Al‐Jedai, Khalid Al Sulaiman	5
10	Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study 2021 ·International Journal of Infectious Diseases ·Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Eljaaly, Aisha Alharbi, (unknown), (unknown), (unknown), Hisham A. Badreldin, Shmeylan Al Harbi, (unknown), (unknown), Ramesh Vishwakarma, Abdulmalik Alkatheri	34
11	Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study 2021 ·Critical Care ·Khalid Al Sulaiman, Ohoud Aljuhani, (unknown), Asma M. Alshahrani, Aisha Alharbi, (unknown), Majed Al Jeraisy, Shmeylan Al Harbi, (unknown), (unknown), (unknown), (unknown), (unknown), Ramesh Vishwakarma, Ghassan Al Ghamdi	24
12	How Do Pelvic Parameters Correlate With Postoperative Outcomes When the Parameters Are Not Measured Preoperatively in Patients Undergoing Instrumented Lumbar Fusion? 2021 ·Cureus ·(unknown), (unknown), Aisha Alharbi, (unknown), (unknown)	2
13	Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study 2021 ·Critical Care ·Khalid Al Sulaiman, Ohoud Aljuhani, (unknown), (unknown), (unknown), (unknown), Aisha Alharbi, (unknown), Shmeylan Al Harbi, Ramesh Vishwakarma, Ghazwa B. Korayem	23
14	Impact of Helicobacter pylori on hematological parameters among Saudi population 2021 ·Saudi Medical Journal ·Wesam A. Nasif, (unknown), Hiba S. Al-Amodi, (unknown), (unknown), (unknown), (unknown), (unknown), Aisha Alharbi	7
15	The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study 2021 ·BMC Infectious Diseases ·Khalid Al Sulaiman, Abdulrahman Alshaya, Ohoud Aljuhani, (unknown), (unknown), Ramesh Vishwakarma, (unknown), (unknown), (unknown), (unknown), Aisha Alharbi, Shmeylan Al Harbi	5
16	Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): A multicenter cohort study 2021 ·SHILAP Revista de lepidopterología ·Khalid Bin Saleh, (unknown), Khalid Al Sulaiman, Ohoud Aljuhani, (unknown), Aisha Alharbi, Ramesh Vishwakarma, Abdulkareem Albekairy, (unknown), (unknown), (unknown), (unknown), (unknown), Hosam M. Zowawi, Hisham A. Badreldin	4
17	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study 2021 ·Scientific Reports ·Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Saleh, Hisham A. Badreldin, (unknown), (unknown), Aisha Alharbi, (unknown), Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma, (unknown)	41
18	Author Correction: Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study 2021 ·Scientific Reports ·Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Saleh, Hisham A. Badreldin, (unknown), (unknown), Aisha Alharbi, (unknown), Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma, (unknown)	3
19	Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis 2019 ·International Journal of Antimicrobial Agents ·Khalid Eljaaly, (unknown), (unknown), Aisha Alharbi, Hani Z. Asfour	21
20	Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections 2019 ·Drugs ·Khalid Eljaaly, Aisha Alharbi, Samah Alshehri, Jessica K. Ortwine, Jason M. Pogue	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact